As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%
Biotech major Amgen $AMGN has decided to cut its losses, and the price, of its cholesterol drug Repatha in a scramble to claw back its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
